JP2010513441A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010513441A5 JP2010513441A5 JP2009542206A JP2009542206A JP2010513441A5 JP 2010513441 A5 JP2010513441 A5 JP 2010513441A5 JP 2009542206 A JP2009542206 A JP 2009542206A JP 2009542206 A JP2009542206 A JP 2009542206A JP 2010513441 A5 JP2010513441 A5 JP 2010513441A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- hal
- formula
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 239000002872 contrast media Substances 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 125000002947 alkylene group Chemical group 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 238000003384 imaging method Methods 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 239000002243 precursor Substances 0.000 claims 3
- 230000002285 radioactive effect Effects 0.000 claims 3
- 125000006594 (C1-C3) alkylsulfony group Chemical group 0.000 claims 2
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 2
- -1 fluoroacyl Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 102000009410 Chemokine receptor Human genes 0.000 claims 1
- 108050000299 Chemokine receptor Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005059 halophenyl group Chemical group 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052755 nonmetal Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0625523.6 | 2006-12-21 | ||
| GBGB0625523.6A GB0625523D0 (en) | 2006-12-21 | 2006-12-21 | In vivo imaging agents |
| PCT/GB2007/004880 WO2008075040A2 (en) | 2006-12-21 | 2007-12-19 | In vivo imaging agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010513441A JP2010513441A (ja) | 2010-04-30 |
| JP2010513441A5 true JP2010513441A5 (enExample) | 2011-01-13 |
| JP5431954B2 JP5431954B2 (ja) | 2014-03-05 |
Family
ID=37734613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009542206A Expired - Fee Related JP5431954B2 (ja) | 2006-12-21 | 2007-12-19 | ＩｎＶｉｖｏ造影剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20110129419A1 (enExample) |
| EP (1) | EP2125038B1 (enExample) |
| JP (1) | JP5431954B2 (enExample) |
| CN (1) | CN101678129B (enExample) |
| AT (1) | ATE555814T1 (enExample) |
| ES (1) | ES2384002T3 (enExample) |
| GB (1) | GB0625523D0 (enExample) |
| WO (1) | WO2008075040A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7344702B2 (en) | 2004-02-13 | 2008-03-18 | Bristol-Myers Squibb Pharma Company | Contrast agents for myocardial perfusion imaging |
| EP2114873B1 (en) | 2006-12-26 | 2013-02-20 | Lantheus Medical Imaging, Inc. | N-[3-bromo-4-(3- [18f]fluoropropoxy)-benzyl]-guanidine for imaging cardiac innervation |
| EP2036578A1 (en) * | 2007-09-13 | 2009-03-18 | Bayer Schering Pharma Aktiengesellschaft | Diagnostic agents for positron emission imaging using F-18 radio labeled amino-alcohols |
| US8936777B2 (en) | 2010-02-08 | 2015-01-20 | Lantheus Medical Imaging, Inc. | Methods and apparatus for synthesizing imaging agents, and intermediates thereof |
| WO2011143360A2 (en) | 2010-05-11 | 2011-11-17 | Lantheus Medical Imaging, Inc. | Compositions, methods and systems for the synthesis and use of imaging agents |
| CN101921224B (zh) * | 2010-05-21 | 2012-01-18 | 中国人民解放军军事医学科学院生物工程研究所 | 1-（3-氨基丙基）哌嗪-4-氨基酰胺类化合物及其制备方法与应用 |
| WO2012074840A2 (en) * | 2010-11-22 | 2012-06-07 | The General Hospital Corporation | Compositions and methods for in vivo imaging |
| EP2753605B1 (en) * | 2011-09-09 | 2019-03-27 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| AU2013203000B9 (en) | 2012-08-10 | 2017-02-02 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| WO2018026965A1 (en) | 2016-08-02 | 2018-02-08 | Isi Life Sciences, Inc. | Compositions and methods for detecting cancer cells in a tissue sample |
| US20180036312A1 (en) * | 2016-08-02 | 2018-02-08 | ISI Life Sciences Inc. | Novel Scaffolds for Intracellular Compound Delivery for the Detection of Cancer Cells |
| US10753942B2 (en) | 2017-05-15 | 2020-08-25 | Indicator Systems International, Inc. | Methods to detect remnant cancer cells |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9912406A (pt) * | 1998-07-28 | 2001-04-24 | Smithkline Beecham Corp | Compostos de anilida substituida e métodos |
| JP3722700B2 (ja) * | 1999-05-04 | 2005-11-30 | シェーリング コーポレイション | Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 |
| PE20010628A1 (es) * | 1999-10-01 | 2001-06-18 | Takeda Chemical Industries Ltd | Compuestos de amina ciclica, su produccion y su uso |
| ES2233479T3 (es) * | 1999-12-03 | 2005-06-16 | Ono Pharmaceutical Co., Ltd. | Derivados de triazaespiro (5,5) undecano y composiciones farmaceuticas que los comprenden, como ingrediente activo. |
| GB0005642D0 (en) * | 2000-03-10 | 2000-05-03 | Astrazeneca Uk Ltd | Chemical compounds |
| BR0112856A (pt) * | 2000-07-31 | 2003-07-01 | Smithkline Beecham Plc | Método para o tratamento dos distúrbios, composto ou um sal ou solvato deste, processo para a preparação dos mesmos, composição farmacêutico, método de tratamento e/ou profilaxia de um ou mais dos distúrbios, uso de um composto, e, método para o tratamento de diabetes, grande depressão, depressão manìaca, ansiedade, esquizofrenia e distúrbios do sono, em mamìferos humanos e não humanos |
| UY27003A1 (es) | 2000-11-06 | 2002-07-31 | Schering Ag | Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer |
| GB0115927D0 (en) | 2001-06-29 | 2001-08-22 | Nycomed Amersham Plc | Solid-phase nucleophilic fluorination |
| GB0115929D0 (en) | 2001-06-29 | 2001-08-22 | Nycomed Amersham Plc | Solid-phase electrophilic fluorination |
| SE0103819D0 (sv) * | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
| GB0127547D0 (en) * | 2001-11-16 | 2002-01-09 | Astrazeneca Ab | Chemical compounds |
| AU2006227133A1 (en) | 2005-03-22 | 2006-09-28 | Georgetown University | Delivery systems and methods for diagnosing and treating cardiovascular diseases |
-
2006
- 2006-12-21 GB GBGB0625523.6A patent/GB0625523D0/en not_active Ceased
-
2007
- 2007-12-19 CN CN2007800466940A patent/CN101678129B/zh not_active Expired - Fee Related
- 2007-12-19 EP EP07848610A patent/EP2125038B1/en not_active Not-in-force
- 2007-12-19 WO PCT/GB2007/004880 patent/WO2008075040A2/en not_active Ceased
- 2007-12-19 JP JP2009542206A patent/JP5431954B2/ja not_active Expired - Fee Related
- 2007-12-19 US US12/519,398 patent/US20110129419A1/en not_active Abandoned
- 2007-12-19 AT AT07848610T patent/ATE555814T1/de active
- 2007-12-19 ES ES07848610T patent/ES2384002T3/es active Active
-
2012
- 2012-12-18 US US13/718,135 patent/US20130129626A1/en not_active Abandoned
- 2012-12-18 US US13/718,124 patent/US20130129625A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010513441A5 (enExample) | ||
| Wang et al. | A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain | |
| JP2013528180A5 (enExample) | ||
| JP2006507265A5 (enExample) | ||
| JP2020514300A5 (enExample) | ||
| JP2007511494A5 (enExample) | ||
| JP2010523599A5 (enExample) | ||
| CN101657454B (zh) | 18f-标记的叶酸类 | |
| JP2006526646A5 (enExample) | ||
| JP2020517616A5 (enExample) | ||
| JP2009535358A5 (enExample) | ||
| JP5431954B2 (ja) | ＩｎＶｉｖｏ造影剤 | |
| JP2008504292A5 (enExample) | ||
| JP2009526034A5 (enExample) | ||
| JP2007501793A5 (enExample) | ||
| JP2009530424A5 (enExample) | ||
| JP2014519507A5 (enExample) | ||
| JP2004534846A5 (enExample) | ||
| JP2014530852A5 (enExample) | ||
| US10973936B2 (en) | 18F-saccharide-folates | |
| JP2004517098A5 (enExample) | ||
| US20250222122A1 (en) | Psma targeted conjugate compounds and uses thereof | |
| JP2007500730A5 (enExample) | ||
| JP2018530582A5 (enExample) | ||
| JP2020505354A5 (enExample) |